.png)
Transforming Scientific Expertise into Breakthrough Medicines
From discovery to the clinic, Toxistrategy delivers tailored nonclinical safety solutions to meet your program's unique challenges. Whether navigating toxicology strategy, IND-enabling packages or regulatory authoring, we provide unmatched
expertise to ensure your therapeutic reaches its full potential.
SERVICES
Nonclinical
Strategy
Nonclinical development of assets from discovery to clinic, including overall strategy, timeline management, budget planning and investor relations.
Study
Execution
End-to-end nonclinical study execution including CRO management, protocol development, study monitoring, and report authoring.
Regulatory
Submission
Authoring and coordination of nonclinical regulatory documents including INDs, CTAs, IBs, BBs, as well as SEND dataset oversight.
Download an overview of our services:
WHO WE ARE
Dessi McEntee, MS, DABT
Owner & Consultant
Dessi is a board-certified toxicologist with a rare blend of expertise that places her among the leading nonclinical safety professionals in the industry. With over a decade of hands-on experience in exploratory and GLP nonclinical sciences across the pharmaceutical and biotech sectors, she has successfully led Toxicology, Safety Pharmacology, and DART strategies across a wide range of therapeutics. Her leadership has been instrumental in advancing numerous critical medicines to the clinic, and her track record in regulatory submissions is flawless.
Toxistrategy is not a big consulting firm—it’s a one-woman powerhouse. When you work with Dessi, you get direct access to a dedicated expert who delivers a tailored, high-touch service designed to drive your program forward. No bloated teams, no wasted hours—just smart, strategic guidance to turn your breakthrough into reality.
